(Q37809841)

23 August 2017

title

Drugs in development for tuberculosis (English)

1 reference

23 August 2017

0 references

Ann M Ginsberg

1 reference

23 August 2017

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

2201-2214

1 reference

Investigations into the mechanism of action of the antibacterial agent norfloxacin

23 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11538170-000000000-00000

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

21 January 2018

1 reference

12 December 2020

Linezolid in the treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

12 December 2020

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

1 reference

12 December 2020

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

1 reference

12 December 2020

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen

1 reference

12 December 2020

Outpatient gatifloxacin therapy and dysglycemia in older adults

1 reference

12 December 2020

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies

1 reference

12 December 2020

Linezolid: a review of safety and tolerability

1 reference

12 December 2020

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

1 reference

12 December 2020

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

1 reference

12 December 2020

Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations

1 reference

12 December 2020

New vaccines against tuberculosis

1 reference

12 December 2020

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

12 December 2020

Biology of bacterial deoxyribonucleic acid topoisomerases

1 reference

12 December 2020

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

1 reference

12 December 2020

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action

1 reference

12 December 2020

Cardiotoxicity of fluoroquinolones

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

1 reference

12 December 2020

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

12 December 2020

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

12 December 2020

Gatifloxacin and moxifloxacin: two new fluoroquinolones

1 reference

12 December 2020

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

12 December 2020

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

1 reference

12 December 2020

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

1 reference

12 December 2020

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

1 reference

12 December 2020

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

12 December 2020

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

1 reference

12 December 2020

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

12 December 2020

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

1 reference

12 December 2020

Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis

1 reference

12 December 2020

Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

1 reference

12 December 2020

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

1 reference

12 December 2020

New vaccines for tuberculosis

1 reference

12 December 2020

Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?

1 reference

12 December 2020

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

1 reference

12 December 2020

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

1 reference

12 December 2020

Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects

1 reference

12 December 2020

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

12 December 2020

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

1 reference

12 December 2020

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

1 reference

12 December 2020

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

1 reference

12 December 2020

Activity of moxifloxacin against mycobacteria

1 reference

12 December 2020

The quest for biomarkers in tuberculosis

1 reference

12 December 2020

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

1 reference

12 December 2020

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

12 December 2020

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

12 December 2020

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis

1 reference

12 December 2020

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

1 reference

12 December 2020

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

1 reference

12 December 2020

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis

1 reference

12 December 2020

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

1 reference

12 December 2020

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro

1 reference

12 December 2020

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

Quinolone-induced QT interval prolongation: a not-so-unexpected class effect

1 reference

12 December 2020

HIV infection-related tuberculosis: clinical manifestations and treatment

1 reference

12 December 2020

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

1 reference

12 December 2020

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

12 December 2020

Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis

1 reference

12 December 2020

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis

1 reference

12 December 2020

Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo

1 reference

12 December 2020

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

1 reference

12 December 2020

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor

1 reference

12 December 2020

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

1 reference

12 December 2020

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

12 December 2020

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

12 December 2020

Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development

1 reference

12 December 2020

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis

1 reference

12 December 2020

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

1 reference

12 December 2020

Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains

1 reference

12 December 2020

Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

1 reference

12 December 2020

Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis

1 reference

12 December 2020

Cytokines as immunomodulators in tuberculosis therapy.

1 reference

12 December 2020

Tuberculosis control and elimination 2010–50: cure, care, and social development

1 reference

12 December 2020

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

1 reference

12 December 2020

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

1 reference

12 December 2020

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

1 reference

12 December 2020

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

1 reference

12 December 2020

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

1 reference

12 December 2020

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

1 reference

12 December 2020

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

1 reference

12 December 2020

Diarylquinolines target subunit c of mycobacterial ATP synthase

1 reference

12 December 2020

10.2165/11538170-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1019705937

0 references

1 reference